A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial
Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Trever G. Bivona(University of California, San Francisco), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Richa Dua(Revolution Medicines (United States)), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), A. Chen(Revolution Medicines (United States)), Pasi A. Jänne(Harvard University), S. Gail Eckhardt(Livestrong Foundation), Jorge H. Limón-Pacheco(University of Colorado Denver), Eric B. Haura(Moffitt Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), R. Jeremy Nichols(St. Jude Children's Research Hospital), Howard A. Burris(Deaconess Hospital), J.S. Wang(Sichuan University), Kimmie Ng(Dana-Farber Cancer Institute), Jonathan W. Riess(University of California Davis Medical Center), Viola W. Zhu(University of California, Irvine), Z. Wang(Revolution Medicines (United States)), Josie Hayes(University of California, Berkeley), Anna Capasso(The University of Texas at Austin), Marianna Koczywas(City Of Hope National Medical Center)
Cited by 74
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k